Cognition Therapeutics shares are trading lower after the company released topline data from Phase 2 SEQUEL Study Of CT1812 in 16 adults with mild-to-moderate Alzheimer's disease
Portfolio Pulse from Benzinga Newsdesk
Cognition Therapeutics has released topline data from its Phase 2 SEQUEL Study of CT1812 in 16 adults with mild-to-moderate Alzheimer's disease, causing its shares to trade lower.
June 28, 2023 | 2:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cognition Therapeutics' stock is trading lower following the release of topline data from its Phase 2 SEQUEL Study of CT1812.
The release of topline data from a clinical trial is a significant event for a biotech company. The fact that Cognition Therapeutics' shares are trading lower suggests that the market may have had negative perceptions of the data, which could impact the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100